Passage Bio, Inc. Form 8-K Summary
Reporting period and context: This Form 8-K was filed by Passage Bio, Inc. (Nasdaq: PASG) under Item 5.02. The report date was May 14, 2021, and the filing was signed May 18, 2021. The company is a Delaware biotechnology company; the filing concerns changes in senior management.
Material Management Changes
- Chief Financial Officer: Richard S. Morris notified the company on May 14, 2021 that he would resign effective May 30, 2021 to pursue other opportunities.
- The company stated that Mr. Morris’s departure was not related to disagreements concerning operations, financial statements, internal controls, auditors, policies, or practices.
- The company was conducting an ongoing search for a successor CFO.
- Chief Medical Officer: Passage Bio and Dr. Gary Romano mutually agreed to his departure on May 18, 2021. His last day was May 18, 2021, and he was pursuing other opportunities.
- Interim medical leadership: Dr. Eliseo Salinas, Chief Research and Development Officer since March 22, 2021, assumed the interim CMO role. The company was conducting an ongoing search for a permanent successor.
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Outlook, Risks, and Unusual Items
The departures of the CFO and CMO, together with the pending searches for permanent successors, may create management-transition and execution risks. The filing does not provide financial guidance, operating forecasts, or additional contingencies. It states that the CFO’s resignation was not due to disagreements with the company.
Key Facts for Investors to Verify
- Whether a permanent CFO and permanent CMO were subsequently appointed.
- Whether the management changes affected financial reporting, internal controls, clinical development, or regulatory activities.
- The company’s financial condition, cash runway, operating expenses, and financing needs in subsequent filings.
- The filing’s chronology: although the report date is May 14, 2021, the CMO departure and signature occurred on May 18, 2021.